Verano Holdings (VRNO) Change in Accured Expenses (2021 - 2026)
Verano Holdings' (VRNO) quarterly Change in Accured Expenses came in at -$15.7 million in Q1 2026, down 74.1% year-on-year from -$60.7 million in Q1 2025, and down 489.04% on a QoQ basis from $4.0 million in Q4 2025.
Verano Holdings (VRNO) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Change in Accured Expenses data on file, last reported at -$15.7 million in Q1 2026.
- On a quarterly basis, Change in Accured Expenses fell 74.1% year-over-year to -$15.7 million in Q1 2026; TTM through Mar 2026 was -$12.2 million, a 31.07% increase from a year earlier, with the FY2025 full-year figure at -$5.5 million, up 67.69% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$15.7 million, down from $4.0 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for VRNO reached as high as $32.2 million in Q4 2022 and fell as low as -$18.0 million in Q3 2022.
- Historically, Change in Accured Expenses has averaged -$1.5 million across 5 years, with a median of -$5.2 million in 2023.
- On a YoY basis, Change in Accured Expenses climbed as much as 203.91% in 2022 and fell as far as 1092.79% in 2022.
- Year by year, Change in Accured Expenses stood at $32.2 million in 2022, then declined by 19.29% to $26.0 million in 2023, then slumped by 139.64% to -$10.3 million in 2024, then soared by 139.21% to $4.0 million in 2025, then plunged by 489.04% to -$15.7 million in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$15.7 million in Q1 2026, $4.0 million in Q4 2025, and -$1.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.58 Bn | 86.72 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.33 Bn | 30.39 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.29 Bn | 18.49 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.93 Bn | 16.62 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.21 Bn | 785.00 Mn | - |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | -15.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.72 Mn |
| Mar 31, 2026 | -15.72 Mn |
| Dec 31, 2025 | 4.04 Mn |
| Dec 31, 2025 | 4.04 Mn |
| Sep 30, 2025 | -1.43 Mn |
| Sep 30, 2025 | -1.43 Mn |
| Jun 30, 2025 | 939,000.00 |
| Jun 30, 2025 | 939,000.00 |
| Mar 31, 2025 | -9.03 Mn |
| Mar 31, 2025 | -9.03 Mn |
| Dec 31, 2024 | -10.31 Mn |
| Dec 31, 2024 | -10.31 Mn |
| Sep 30, 2024 | -1.61 Mn |
| Sep 30, 2024 | -1.61 Mn |
| Jun 30, 2024 | 3.29 Mn |
| Jun 30, 2024 | 3.29 Mn |
| Mar 31, 2024 | -8.33 Mn |
| Mar 31, 2024 | -8.33 Mn |
| Dec 31, 2023 | 26.00 Mn |
| Dec 31, 2023 | 26.00 Mn |